POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment
TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium – 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed.
“CanProbe’s NET clinical program has helped many patients in Ontario who previously had no other options for treatment,” says Dr. Joe McCann, Chief Executive Officer of POINT Biopharma. “We are excited to extend access to this treatment by leveraging CanProbe’s intellectual property to seek regulatory approvals, with the goal of helping patients in need around the world.” POINT is currently building a state-of-the-art manufacturing facility in Indianapolis, Indiana, to ensure sufficient production capacity is available for Lu-DOTATATE as well as the other drugs in its pipeline.
“We are looking forward to working with POINT Biopharma on the commercialization of Lu-DOTATATE,” says Dr. Luke Brzozowski, President of CanProbe. “We believe POINT is the ideal partner to make this treatment accessible to patients in Ontario and across the globe.” CanProbe is also developing the related diagnostic agent, Gallium – 68 Octreotate (Ga-DOTATATE), with cyclotron-produced Ga-68 using solid target technology.
CanProbe (canprobe.ca ) is a joint venture between the University Health Network (UHN, uhn.ca ) and the Centre for Probe Development and Commercialization (CPDC, imagingprobes.ca ) to create a Canadian Centre of Excellence for the development, translation, utilization and commercialization of radiopharmaceuticals. CanProbe provides access to specialized expertise that supports the development of new radiopharmaceuticals, with proven experience translating products to the clinical setting, and world-class, GMP, manufacturing capabilities that operate in accordance with FDA, Health Canada and European regulations.
About POINT Biopharma
POINT Biopharma is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, strategic partnerships in radio-isotope supply, manufacturing technology and novel direct to patient targeting to revolutionize theragnostic drug development and radioligand commercialization.
VP, Corporate Affairs
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Montreal Heart Institute23.1.2021 07:02:08 CET | Press release
Colchicine reduces the risk of COVID-19-related complications
Zealand Pharma22.1.2021 22:06:25 CET | Press release
Zealand Pharma announces update to 2020 financial guidance
Sveriges Riksbank22.1.2021 20:35:53 CET | Press release
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS
Waturu Holding A/S22.1.2021 19:49:42 CET | Press release
Waturu Holding A/S – convening of an extraordinary general meeting
Waturu Holding A/S22.1.2021 19:49:41 CET | Pressemeddelelse
Waturu Holding A/S – indkaldelse til ekstraordinær generalforsamling
Waturu Holding A/S22.1.2021 19:39:41 CET | Press release
Waturu Holding A/S – change in board of directors
Waturu Holding A/S22.1.2021 19:39:40 CET | Pressemeddelelse
Waturu Holding A/S – ændring i bestyrelsen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom